Bladder cancer trial combining radiation and Sacituzumab
Treatments studied
Part of Cancer, Kidney & urinary clinical trials.
This Phase 1 study tests whether a new bladder-cancer treatment plan—radiation given at the same time as sacituzumab govitecan—can help people with muscle-invasive bladder cancer without starting with traditional chemo/radiation. Because it’s early-stage, the main goal is safety and learning the best way to use this combination to preserve the bladder.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have confirmed muscle-invasive bladder cancer (T2 to T4a, and no spread to nearby lymph nodes or distant sites).
- You have not had prior chemotherapy for this bladder cancer, and you must be willing to skip chemo that makes radiation work differently.
- You must have enough strength and organ function (blood counts and liver/kidney tests within required limits).
- Your bladder must be able to function well enough for bladder-preservation; no bilateral (both sides) blocked urine flow.
- You must have a transurethral resection (TURBT) within 60 days and up-to-date scans (CT or MRI) within 60 days for staging.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two drugs—one that targets cancer cells directly and another that helps your immune system fight the cancer—to try to get rid of the cancer without needing to remove your bladder. If you have muscle-invasive bladder cancer and are unable or unwilling to have bladder removal surgery, this approach might be an option for you.
This trial tests a combination of two drugs (sacituzumab govitecan and nivolumab) given after surgery to prevent the return of muscle-invasive bladder cancer. It is for patients whose cancer has a high chance of coming back despite surgery.
This trial tests a new drug combination (pembrolizumab and sacituzumab govitecan) against standard treatment for advanced bladder cancer that has spread or cannot be removed by surgery. It's for people who have already tried an immunotherapy drug like pembrolizumab and another drug called enfortumab vedotin.
This trial is testing a drug called sacituzumab govitecan, sometimes combined with atezolizumab (an immunotherapy), for rare cancers of the bladder, urinary tract, kidney, or penis. The goal is to see if these treatments work well for people whose cancers have not responded to other options.
This trial is for people with advanced bladder cancer (urothelial cancer) that has spread or can't be removed. It tests a new drug called sacituzumab tirumotecan against standard chemotherapy options to see if it works better.
This trial tests a new drug, sacituzumab tirumotecan, for people with advanced kidney or bladder cancers that have not responded to standard treatments. The drug targets a protein on cancer cells to deliver treatment directly, potentially slowing or stopping tumor growth.
Hear when a new Muscle-Invasive Bladder Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.